- Home
- SKYE vs BYM Comparison
SKYE vs BYM Comparison
Compare SKYE & BYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BYM
- Stock Information
- Founded
- SKYE 2012
- BYM 2002
- Country
- SKYE United States
- BYM United States
- Employees
- SKYE N/A
- BYM N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BYM Investment Managers
- Sector
- SKYE Health Care
- BYM Finance
- Exchange
- SKYE Nasdaq
- BYM Nasdaq
- Market Cap
- SKYE 73.4M
- BYM 270.7M
- IPO Year
- SKYE N/A
- BYM N/A
- Fundamental
- Price
- SKYE $4.32
- BYM $10.48
- Analyst Decision
- SKYE Buy
- BYM
- Analyst Count
- SKYE 6
- BYM 0
- Target Price
- SKYE $16.60
- BYM N/A
- AVG Volume (30 Days)
- SKYE 1.9M
- BYM 60.2K
- Earning Date
- SKYE 08-08-2025
- BYM 01-01-0001
- Dividend Yield
- SKYE N/A
- BYM 4.49%
- EPS Growth
- SKYE N/A
- BYM N/A
- EPS
- SKYE N/A
- BYM N/A
- Revenue
- SKYE N/A
- BYM N/A
- Revenue This Year
- SKYE N/A
- BYM N/A
- Revenue Next Year
- SKYE N/A
- BYM N/A
- P/E Ratio
- SKYE N/A
- BYM N/A
- Revenue Growth
- SKYE N/A
- BYM N/A
- 52 Week Low
- SKYE $1.14
- BYM $9.30
- 52 Week High
- SKYE $8.26
- BYM $11.77
- Technical
- Relative Strength Index (RSI)
- SKYE 81.18
- BYM 47.07
- Support Level
- SKYE $2.12
- BYM $10.40
- Resistance Level
- SKYE $2.22
- BYM $10.49
- Average True Range (ATR)
- SKYE 0.35
- BYM 0.09
- MACD
- SKYE 0.20
- BYM 0.00
- Stochastic Oscillator
- SKYE 84.03
- BYM 31.82
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.